Hepion (HEPA) Executive Chairman Vincent LoPriore Acquires Warrants

What Happened

• Vincent S. LoPriore, Executive Chairman and Director of Hepion Pharmaceuticals (HEPA), reported an acquisition of 12,500,000 derivative securities (warrants) on Sept 3, 2026. The reported price was $0.00 (no cash paid) and the reported aggregate value is $0. The instrument is a warrant (derivative), not an immediate equity share purchase.

Key Details

• Transaction date: 2026-09-03; Form 4 filed: 2026-09-14.
• Transaction type: P (Purchase) of derivative securities (warrants).
• Amount acquired: 12,500,000 warrants at $0.00 per unit; reported value $0.
• Shares owned after transaction: not disclosed in the Form 4 (not reported in the filing).
• Notable footnotes:
  • F1: The warrant is exercisable only upon stockholder approval of an increase in the Company’s authorized common shares.
  • F2: Mr. LoPriore is the Managing Member of Gravitas Capital LP and, in that capacity, has the right to vote and dispose of securities held by that entity.
• Filing timeliness: The Form 4 was filed 11 days after the transaction date; this appears later than the standard 2-business-day reporting window for Form 4s.

Context

• This was an acquisition of a derivative instrument (warrants), not an immediate issuance of common stock. Because exercise of these warrants depends on a future shareholder vote to increase authorized shares, they do not currently convert into tradable common shares.
• Derivative acquisitions at $0 can reflect negotiated grants, settlement terms, or other non‑cash transactions; the Form 4 does not explain the underlying business reason. This report is factual and does not imply a view on the company’s prospects.